Condition: Esophageal Squamous Cell Carcinoma · Chemoradiotherapy · Survival · Sponsor: Fudan University
So far, there is no specific clinical guideline for elderly patients (\>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx） or the chemoradiotherapy group (50.4Gy/28Fx；Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.
This description comes directly from the study's public registry record.
Kuaile Zhao, doctor · 18017312534 · kuaile_z@sina.com
ying jia Deng, doctor · 18017312829 · dengjiaying3@sina.com
Always discuss trial participation with your own doctor first.
| Jiangsu Cancer Hospital | Nanjing, Jiangsu, China | Recruiting |
| Huadong Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Fudan Universtiy Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04519905